CCCC

C4 Therapeutics, Inc.

Contracts

Total Value

Stock Metrics

38.2%

Short % Float

11.1d to cover · High squeeze

1.0%

Inst % Float

10 holders · 2026-06-30

Morgan Stanley

Top Holder

7.2% of float

79.6M sh

Public Float

45/100

Dilution Score

Medium

21 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

45/100

MEDIUM

Inst: 1.02% · Top: Morgan Stanley

Biotech Analytics

Biotech / Pharma

23.32

Squeeze risk: HIGHBiotech Grade: F

Insider Buying0

Publications100

Dilution Risk45

Clinical Trials21

Short Interest90